



Nine-month figures for 2010: SSB further increases profit

€ in millions Unaudited figures	9 months 2010	9 months 2009	Change in %	Change in % (in constant currencies)
Sales revenue	319.0	298.7	+6.8	+4.4
• Europe ¹⁾	169.9	173.6	-2.1	-2.5
• North America ¹⁾	85.0	72.5	+17.3	+13.0
• Asia Pacific ¹⁾	51.0	40.5	+25.8	+17.5
• Other Markets ¹⁾	13.1	12.1	+8.0	+8.0
EBITA ²⁾	50.0	46.4	+7.6	
EBITA margin ²⁾	15.7	15.5		
Net profit ²⁾³⁾	31.0	26.5	+16.9	
Earnings per share in € ²⁾³⁾	1.91	1.56	+22.2	

¹⁾ According to customers' location

²⁾ Underlying

³⁾ Excluding amortization

The Sartorius Stedim Biotech Group uses earnings before interests, taxes and amortization (EBITA) as the key figure for measuring performance and profitability of the Group. Amortization refers only to any potential amortization of goodwill and of the intangible assets measured within the scope of purchase price allocation according to IFRS 3 "Business Combinations." The key indicator "underlying EBITA" corresponds to the EBITA adjusted for non-operating items.

Strong growth in Asia/Pacific and the US; flat development in Europe

In the first nine months of 2010, order intake and sales revenue for Sartorius Stedim Biotech (SSB) continued to grow. As expected, order volume rose, particularly in the Asia/Pacific region, for equipment business comprising bioreactor systems. Also, business with single-use products again proved to be a growth driver; with double digit growth rates generated in North America and Asia/Pacific. Sales in Europe dipped slightly due to the phase-out of extraordinary business with producers of H1N1 vaccines.

Further increase in profitability

In the first nine months, Sartorius Stedim Biotech increased its operating earnings before interest, taxes and amortization and adjusted for extraordinary expenses (=underlying EBITA) from €46.4 million to €50.0 million. The respective underlying EBITA margin improved from 15.5% to 15.7%. Extraordinary expenses accounted for €0.9 million in the first nine months of 2010.

Comfortable financial position

Reflected by an equity ratio of 56.1% and a net-debt-to-EBITDA ratio of 1.4, the financial position of the Sartorius Stedim Biotech Group stays at a very comfortable level. Triggered by the share buyback program, equity declined from €393.2 million as of December 31, 2009, to €365.4 million as of September 30, 2010.

Sartorius Stedim Biotech S.A.
 Z.I. Les Paluds
 Avenue de Jouques
 B.P. 1051
 13781 Aubagne - France
www.sartorius-stedim.com

Press Contact:
 Petra Kirchhoff
 Phone +49 (0)551.308.1686

Aubagne | Goettingen,
 October 22, 2010

Outlook specified: Growth slightly lower, operating margin slightly higher

Management specified its financial outlook for fiscal 2010: Sales growth is expected to be slightly below previous forecasts, at approx. 5% in constant currencies (earlier within the upper half of the single-digit percentage range), while profitability will be slightly above former guidance. The operating EBITA margin is thus anticipated to increase to approx. 16% (earlier slightly above the year-earlier figure of 15.0%). Furthermore, operating cash flow is projected to be significantly positive.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference Call and Webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Friday, October 22, 2010, at 2:00 p.m. Central European Time (CET), in a webcast teleconference. You may dial into the teleconference starting at 1:45 p.m. CET at the following numbers:

Germany: +49 (0)69 2222 2245

France: +33 (0)1 70 99 42 66

UK: +44 (0)20 7138 0825

USA: +1 212 444 0481

The dial-in code is: 4240400

To view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions." Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approximately 2,400 people, and in 2009 earned sales revenue of 401.2 million euros.

Contact: Petra Kirchhoff; Vice President of Group Corporate Communications;
Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany;
Phone: +49(0)551/ 308-1686; Fax: +49(0)551/ 308-3410;
e-mail: petra.kirchhoff@sartorius.com; <http://www.sartorius-stedim.com>